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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.035Soft tissue sarcomas are a heterogeneous group of tumors associated with poor clinical outcome. Although
a subset of soft tissue sarcomas is characterized by simple karyotypes and recurrent chromosomal
translocations, the mechanisms driving cytogenetically complex sarcomas are largely unknown. Clinical
evidence led us to partially inactivate Pten and Tp53 in the smooth muscle lineage of mice, which
developed high-grade undifferentiated pleomorphic sarcomas, leiomyosarcomas, and carcinosarcomas
that widely recapitulate the human disease, including the aberrant karyotype and metastatic behavior.
Pten was found haploinsufﬁcient, whereas the wild-type allele of Tp53 invariably gained point mutations.
Gene expression proﬁles showed up-regulated Notch signaling in PtenD/þTp53D/þ tumors compared with
Ptenþ/þTp53D/þ tumors. Consistently, Pten silencing exacerbated the clonogenic and invasive potential
of Tp53-deﬁcient bone marrowederived mouse mesenchymal stem cells and tumor cells and activated the
Notch pathway. Moreover, the increased oncogenic behavior of PtenD/þTp53D/þ and shPten-transduced
Ptenþ/þTp53D/þ tumor cells was counteracted by treatment with a g-secretase inhibitor, suggesting that
the aggressiveness of those tumors can be attributed, at least in part, to enhanced Notch signaling. This
study demonstrates a cooperative role for Pten and Tp53 suppression in complex karyotype sarcomas while
establishing Notch as an important functional player in the cross talk of these pathways during tumor
progression. Our results highlight the importance of molecularly subclassifying patients with high-
grade sarcoma for targeted treatments. (Am J Pathol 2013, 182: 2015e2027; http://dx.doi.org/
10.1016/j.ajpath.2013.02.035)Supported by American Cancer Society grant RSG-08-161-01-DDC,
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for Research on Cancer, Lyon, France.Soft tissue sarcomas (STSs) are rare but represent some of the
most aggressive adult and childhood malignancies. Believed
to originate from as-yet poorly deﬁned mesenchymal stem/
progenitor cells, they can arise in connective tissue (eg, ten-
dons, fat, and fascia), muscle, nerve, or blood vessel.1 How-
ever, regardless of the tissue of origin, STSs share an overall
poor prognosis.2 One reason is that they are frequently
discovered at more advanced stages, but the deeper problem is
that there is limited understanding of their pathogenesis and,
thus, little guidance for developing targeted therapies. Al-
though some STSs harbor characteristic chromosomal trans-
locations or simple genetic mutations, the rest show more
pronounced genomic instability, with a complex karyotypestigative Pathology.
.and multiple chromosomal aberrations that are not consistent
among tumors within a particular subtype.1,3 This larger
category, for which there have been no driver mutations
identiﬁed, includes high-grade undifferentiated pleomorphic
Guijarro et alsarcomas (HGUPSs; the most common sarcomas diagnosed
in the extremities), leiomyosarcomas (LMSs; which arise in
smooth muscle), and carcinosarcomas (CSs; a mixed epithe-
lial/connective tissue malignancy).1,3
Despite the heterogeneity of STSs, there are hints that
some alterations are shared among multiple tumor types.
Individuals with Li-Fraumeni syndrome, caused by a germ-
line TP53 mutation, have an increased tendency to develop
STSs, and several different sarcomas have shown disruptions
in the Tp53 tumor-suppressor pathway.1,3,4 Individuals with
neuroﬁbromatosis type 1, who carry NF1 mutations leading
to up-regulation of Ras signaling, are also predisposed to
develop STS. Mouse models of these diseases replicate the
broad spectrum of neoplasia seen in human patients, but it has
been difﬁcult to engineer in vivo models that develop non-
syndromic forms of sarcoma, particularly HGUPS and LMS.
There may be a requirement for multiple genetic hits (eg,
intramuscular delivery of an adenovirus expressing the Cre
recombinase in mice with conditional mutations in both Kras
and Tp53 initiated high-grade sarcomas with myoﬁbroblastic
differentiation).5 Similarly, uterine LMSs that arose after
Tp53 and BRCA1 were conditionally deleted under the anti-
müllerian hormone type II receptor (Amhr2),6 and simulta-
neous inactivation of both genes signiﬁcantly accelerated
tumor progression. Despite their usefulness, these models
likely represent only a portion of all HGUPSs, LMSs, and/or
CSs, given the molecular heterogeneity of these tumors. In
fact, to our knowledge, there is no mouse model of CS.
We have, therefore, sought to generate mouse models
based on genetic defects widely found in tumor tissue from
patients with STS in the hope that these models would allow
us to dissect molecular pathways frequently involved in
sarcoma formation and metastasis and to test the efﬁcacy of
new therapies. Herein, we describe novel conditional mice
heterozygous for Tp53 and/or Pten in the smooth muscle
(SM) lineage. These mice develop HGUPS, LMS, and CS,
which recapitulate the histological and biological features of
the corresponding human neoplasia, including their meta-
static behavior, and provide insight into the molecular
mechanisms involved in these tumors.
Materials and Methods
Generation of Knockout Mice, Animal Husbandry, and
Genotyping
PtenL/L7,8 and Tp53L/L9 (National Cancer Institute mouse
repository, Bethesda, MD) were intercrossed, and the
progeny were crossed with Tagln-cre23 [Tg(Tagln-cre23)
1Her/J; Jackson Labs, Bar Harbor, ME] mice for smooth
muscleespeciﬁc deletion of one or two alleles of Pten
and Tp53. The mouse cohort followed up for overall survival
up to 27 months included 90 animals: 13 Tagln-creþ/PtenD/þ
Tp53D/þ, 28 Tagln-creþ/PtenD/þTp53þ/þ, 16 Tagln-creþ/
Ptenþ/þTp53D/þ, 5 Tagln-creþ/PtenD/DTp53þ/þ, and 28
control mice (including 2 Tagln-cre/PtenD/þTp53D/þ, 72016Tagln-cre/PtenD/þTp53þ/þ, 1 Tagln-cre/Ptenþ/þTp53D/þ,
3 Tagln-cre/PtenD/DTp53þ/þ, and 15 Tagln-cre/Ptenþ/þ
Tp53þ/þ). Another mouse cohort was maintained to increase
the amount of tumors isolated and explanted. B6;129-
Gt(Rosa)26Sortm2Sho/J mice (Rosa26-LSL-EGFP, number
004077; Jackson Labs10) and B6.129S4-Gt(Rosa)
26Sortm1Sor/J (Rosa26-LSL-LacZ, number 003474; Jackson
Labs11) were obtained. All mice were handled according
to New York University (NYU) Institutional Animal Care
and Use Committee approved protocols (numbers 061108-03
and 100108-01). For genotyping, tail DNA was subjected
to polymerase chain reaction analysis using the primers
and protocols described.7,8,10,11
Mouse Histopathological and IHC Characteristics
Mouse tissue samples collected were ﬁxed in 10% neutral-
buffered formalin, processed, and embedded in parafﬁn,
according to standard protocols. Sections (5 mm thick) were
prepared for antibody detection and H&E staining. Immu-
nohistochemistry (IHC) was conducted following the stan-
dard avidin-biotin immunoperoxidase staining procedure.
Diaminobenzidine was used as the chromogen, and hema-
toxylin was used to counterstain nuclei. Antibodies used
were desmin (DER11, number 2530; Ventana Medical Sys-
tems, Tucson, AZ) and proliferating cell nuclear antigen
(PCNA; PC10, number MS106; Neomarkers, Fremont, CA).
Generation of Cell Lines and Culture Conditions
Tumor fragments were minced in HBSS with antibiotics/
antimycotics (Hyclone Thermo, South Logan, UT) and dis-
sociated by incubation on 100 U/mL collagenase V (Sigma,
St. Louis, MO) for 30 minutes at 37C. Twenty-four hours
later, media were changed to mouse mesenchymal stem cell
medium that consists of Iscove’s modiﬁed Dulbecco’s
medium (Gibco, Grand Island, NY) with 2 mmol/L L-gluta-
mine (Hyclone Thermo), 9% fetal bovine serum (Cell Gro,
Manassas, VA), and 9% donor horse serum (Cell Gro).
RNA Extraction, RT-PCR, and Real-Time PCR Analyses
Total RNA was extracted using Qiazol (Qiagen, Valencia,
CA), followed by RNeasy Mini Kit (Qiagen). Semi-
quantitative RT-PCR was performed by reverse tran-
scribing 500 ng of total RNA with a Taqman Assay kit
(Applied Biosystems, Austin, TX), followed by standard
PCR using RNA-speciﬁc primers. Quantitative real-time
RT-PCR was performed using FastStart SYBR Green
MasterMix (Roche, Basel, Switzerland) and BioRad iCy-
cler equipment (Hercules, CA).
Expression Analysis
Expression proﬁling of PtenD/þTp53D/þ (nZ 4) and Ptenþ/þ
Tp53D/þ (n Z 5) murine HGUPS was performed using theajp.amjpathol.org - The American Journal of Pathology
Table 1 Primers Used for Sequencing, Genotyping, and Expres-
sion Array Validation
Gene No. Sequence
Tp53 11 Forward 50-ATGACTGCCATGGAGGAGTCACA-30
Tp53 11 Reverse 50-TCAGTCTGAGTCAGGCCCCA-30
Tp53 1 Forward 50-CACAAAAACAGGTTAAACCCAG-30
Tp53 1 Reverse 50-AGCACATAGGAGGCAGAGAC-30
Tp53 10 Reverse 50-AAGGGGTATGAGGGACAAGG-30
Pten 2 Forward 50-CATCTCTCTCCTCCTTTTTCTTCA-30
Pten 4 Reverse 50-TTCATGGTATTTTATCCCTCTTGA-30
Pten 2 Reverse 50-CAAACATCATCTTGTGAAACAGC-30
Pten 3 Forward 50-GGCAAATTTTTAAAGGCACAAG-30
Pten 3 Reverse 50-AAGTTGAACTGCTAGCCTCTGG-30
Pten 4 Forward 50-ACTTTGAGTTCCCTCAGCCA-30
Pten 5 Reverse 50-AAAAGTTCCCCTGCTGATGATTTGT-30
Pten 6 Forward 50-TGTTTTTGACCAATTAAAGTAGGCTGTG-30
Pten 7 Forward 50-TTCTCTTGAGCACTGTTTCACAGGC-30
Hes1 Forward 50-AAAGCCTATCATGGAGAAGAGGCG-30
Hes1 Reverse 50-GGAATGCCGGGAGCTATCTTTCTT-30
Notch1 Forward 50-ACACTGACCAACAAATGGAGG-30
Notch1 Reverse 50-GTGCTGAGGCAAGGATTGGA-30
Jak1 Forward 50-CTCTCTGTCACAACCTCTTCGC-30
Jak1 Reverse 50-TTGGTAAAGTAGAACCTCATGCG-30
Ripk1 Forward 50-GAAGACAGACCTAGACAGCGG-30
Ripk1 Reverse 50-CCAGTAGCTTCACCACTCGAC-30
R18s1 Forward 50-TTGTACACACCGCCCGTCGC-30
R18s1 Reverse 50-CTTCTCAGCGCTCCGCCAGG-30
Gapdh Forward 50-ACCGCCGTTATGAAATCTTG-30
Gapdh Reverse 50-CACATTGGGGGTAGGAACAC-30
Notch in Pten/Tp53-Inactivated SarcomasAffymetrix Genechip system (Affymetrix, Santa Clara,
CA). Total RNA was extracted with Qiazol (Qiagen), and
quality and quantity were determined using a Bioanalyzer
(Agilent Technologies, Santa Clara, CA) and Nanodrop
ND-1000 (Thermo Scientiﬁc, Waltham, MA). Total RNA
(100 ng) was used to prepare cDNA following the Affy-
metrix 30IVT Express Kit labeling protocol (Affymetrix).
Standardized array processing procedures recommended by
Affymetrix were performed, including hybridization,
ﬂuidics processing, and scanning of the Affymetrix Mouse
Genome-430 2.0 arrays. The raw data (.cel ﬁles) were
normalized for probe-level summarization by the robust
multichip average and analyzed by using Pavlidis template
matching (P < 0.05). For these steps, GeneSpring software
version GX11 (Agilent Technologies) was used. Gene
set enrichment analysis (GSEA)12,13 was used to identify
signiﬁcantly enriched gene expression patterns underlying
PtenD/þTp53D/þ HGUPS, by querying the C2 (curated
pathways) and C5 (Gene Ontologies) categories of the
GSEA MSigDB, version 3.0 (Broad Institute, Boston,
MA). The raw array data were deposited at the National
Center for Biotechnology Information Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo; accession
number GSE42103).
DNA Extraction, Loss of Heterozygosity, and
Sequencing Analyses
For genomic DNA extraction, formalin-ﬁxed, parafﬁn-
embedded (FFPE) tissues (10 mm thick) were cut and placed on
uncharged glass slides. Tissueswere deparafﬁnizedwith xylene,
washed in ethanol, and digested with proteinase K. DNA was
extracted using the Qiagen FFPE genomic DNA isolation kit.
Total DNA quantity and quality were quantitated using Nano-
drop ND-1000 (Thermo Scientiﬁc). Primer sequences used for
DNA ampliﬁcation are listed in Table 1. For sequencing, PCR
fragments were cloned into pCRII-TOPO vector, and >20
colonies were sequenced using T7 and M13R primers.
Western Blot Analysis
Cell pellets were lysed using radioimmunoprecipitation
(RIPA) assay buffer (Thermo Scientiﬁc), supplemented with
protease and phosphatase inhibitors (Roche). Tumors were
lysed with the same buffer, adding 0.1 mg/mL aprotinin, 0.1
mg/mL leupeptin, and 0.5 mg/mL pepstatin. Protein (30 mg)
was resolved on 4% to 20% Tris-glycine SDS-PAGE gels
(Invitrogen, Carlsbad, CA). Proteins were transferred to
polyvinylidene diﬂuoride (PVDF) membranes, blocked with
1% bovine serum albumin (BSA) in Tris-buffered saline
(TBS)-Tween 0.01% for 1 hour, and incubated overnight at
4C with primary antibody [PTEN, number 9552 (Cell
Signaling, Danvers, MA) and tubulin, number T9026
(Sigma)]. Membranes were incubated with horseradish per-
oxidaseeconjugated secondary antibodies for 1 hour before
development using Enhanced Chemoluminescence PlusThe American Journal of Pathology - ajp.amjpathol.org(ECL Plus), a Western blot detection kit (GE Healthcare,
Piscataway, NJ).
Bone Marrow Extraction
Bonemarrow (BM)was collected byﬂushing the long bones of
murine tibias and femurs with an insulin syringe. BM was
washed with HBSS twice. Cells were plated in a 75-mm2 ﬂask
in complete isolation media, which consisted of RPMI 1640
medium (Gibco, Carlsbad, CA), 9% fetal bovine serum (Cell
Gro), 9%horse serum(HyCloneThermo), 100U/mLpenicillin/
streptomycin (Thermo Scientiﬁc), and 2 mmol/L L-glutamine
(Invitrogen). After 48 hours, adherent cells were washed with
PBS and fresh complete isolationmediumwas added every 3 to
4 days. After 2 weeks in culture, cells were lifted with 0.25%
trypsin (Gibco) and plated for different experiments in complete
expansion medium (mouse mesenchymal stem cell medium).
Adenovirus Infection
BM-derived cells were infected in low serum with Ad5e
CMVeCreegreen ﬂuorescent protein (GFP). Adenoviruses
were purchased from Baylor College of Medicine (Houston,
TX). At 7 hours after infection, mouse mesenchymal stem cell
medium was added and changed every 2 days. After 5 days,
cells were plated.2017
Guijarro et alLentiviral Infection
Lentiviruses were propagated using previously described
methods.14 GIPZ short-hairpin (shPten) and empty vector
were purchased fromOpen Biosystems (Huntsville, AL). Cell
lines were infected 3 and selected with 1 mg/mL puromycin
48 hours after transfection to generate stable cell lines.
Clonability
A total of 0.5, 1, or 2 103 cells were seeded in 6-well plates.
Medium was replaced every 3 days, and after 5 to 10 days,
cells were ﬁxed and stained with 1% crystal violet. After
extensive washing, colonies were counted. When indicated,
cells were treated with 500 nmol/L Compound E (ALX-270-
415-C250; Enzo Life Sciences, Farmingdale, NY).
Growth Curves
A total of 1 103 cells were plated in 96-well plates. Every 2
days, cells were ﬁxed and stained with 1% crystal violet.
After extensive washing, 15% acetic acid was used to
dissolve the stain, and color intensity was quantiﬁed at 595
nm. Relative growth is represented as the percentage of
growth compared with the control. When indicated, cells
were treated with 500 nmol/L Compound E.
Fibronectin Transwell Invasion Assay
A suspension of 8 103 cells was added to cell culture inserts
(Falcon, Austin TX) containing a polycarbonate ﬁlter with
8-mm-diameter pores coated with 100 mg/mL ﬁbronectin and
2.5%bovine serum albumin. Cells were incubated for 19 hours
under standard culture conditions. Tumor cells remaining on
the topside of the membrane were removed, and cells that had
migrated to the underside were ﬁxed and stained with 1%
crystal violet. Five preset ﬁelds per insert were imaged and
scored.When indicated, cells were treated 1 day before seeding
and during the experiment with 500 nmol/L Compound E.
b-Galactosidase Staining
Tissues were ﬁxed in 1% paraformaldehyde/0.2% glutaral-
dehyde in PBS containing 2 mmol/L MgCl2, 5 mmol/L
EGTA, and 0.02% NP-40 at 4C for 2 hours. After rinsing in
PBS and staining with X-Gal for 4 hours, tissues were
dehydrated with isopropanol and embedded in parafﬁn.
Tissue was divided into sections (5 mm thick) and counter-
stained with eosin.
Fluorescence-Activated Cell Sorter Analysis
Fluorescence-activated cell sorting of primary BM cells was
performed on a BD LSR II ﬂow cytometer. Antibodies were
purchased from eBioscience (San Diego, CA): c-kit APC
number 17-1171-82, Stem cell antigen-1 (Sca) PE-Cy72018number 25-5981-82, Myeloid differentiation antigen (Gr1)
APC-Cy7 number 47-5931-82, Macrophage-1 antigen
(Mac1) APC-Cy7 number 47-0112-82, TER-119 APC-Cy7
number 47-5921-82, B220 APC-Cy7 number 47-0452-82,
CD4 APC-Cy7 number 47-0042-82, CD8 APC-Cy7 number
47-0081-82, and IL7R APC-Cy7 number 47-1271-82. Data
were analyzed using FlowJo software version X (10.0.0)
(Tree Star, Ashland, OR).
Karyotyping
Subconﬂuent cultures were treated with 0.05 mg/mL Kar-
yoMAX Colcemid (Invitrogen) for 40 to 60 minutes before
harvesting. Cells were trypsinized to a single-cell suspen-
sion, pelleted at 180  g for 8 minutes, and resuspended in
warm 0.075 mol/L KCl. After an 8-minute incubation at
37C, the hypotonic solution was diluted with three parts of
Carnoy’s ﬁxative (3:1 methanol/glacial acetic acid) and
gently mixed, and the cells were pelleted as before. The
supernatant was removed, and the cell pellet was loosened
by gently ﬂicking the base of the tube. The cells were then
ﬁxed in three changes of ﬁxative. Fixed cell suspensions
were stored at 20C. Fixed metaphase preparations were
dropped onto dry slides, and the quality of spreading was
assessed by phase microscopy. Spreading was adjusted by
altering the drying time, increasing local humidity (water
bath), or applying heat (hotplate). Slides were then air dried
and aged (at 37C for several days or at 60C for several
hours). Aged slides were immersed in 0.08 mg/mL DAPI in
2 standard saline citrate for 3 minutes, rinsed, air dried,
mounted in antifade solution (Vectashield; Vector Labs,
Burlingame, CA), and stored at 4C. DAPI-stained slides
were scanned using a Nikon E800 epiﬂuorescence micro-
scope (Melville, NY) equipped with a digital imaging
system (Applied Spectral Imaging, Vista, CA). Metaphase
images were inverted to resemble conventional G-banding
and karyotyped using BandView software (Applied Spec-
tral Imaging, ASI; Carlsbad, CA). Where possible,
a minimum of 20 metaphases was examined for each
sample. To avoid confusion, abnormal karyotypes were
described according to the International System for Human
Cytogenetic Nomenclature, rather than the Standardized
Genetic Nomenclature for Mice, because the experimental
systems are intended to model human disease.
Patients and Tumor Collection
Parafﬁn blocks of the tumor specimens were obtained from
the NYU Pathology Department at Bellevue Hospital Center
(H10457-014; New York, NY) and Northwestern Univer-
sity (STU7147; Chicago, IL).
Extraction of Tumor Genomic DNA
For FFPE samples, tissue sections from blocks were placed
into microcentrifuge tubes (ﬁve sections, 10 mm thick), andajp.amjpathol.org - The American Journal of Pathology
Notch in Pten/Tp53-Inactivated Sarcomasconsecutive H&E-stained slides were obtained from each
block. Tumor-enriched areas were identiﬁed, and core
punches were taken from the corresponding region of the
block. DNA was extracted from FFPE cores using a Qiagen
DNeasy kit, according to the manufacturer’s directions.
Mass Spectrometric Genotyping
A two-step process was used as previously described.15 DNA
extracted from FFPE blocks was quantiﬁed using picogreen
analysis. Whole genome ampliﬁed DNA was used as input
for multiplex PCR using primers from OncoMap 3 and
OncoMap 3 Extended (Dana-Farber Cancer Institute, Boston,
MA), which together compose 1047 independent assays
interrogating 983 unique mutations across 116 genes. Mass
spectrometric genotyping using iPLEX technology (Seque-
nom Inc, San Diego, CA) was performed, and candidate
mutations identiﬁed were subsequently subject to a second
round of homogeneous Mass-Extend, using independent
primers and probes. Candidate calls were classiﬁed as
aggressive or conservative, depending on their apparent
robustness. Sample quality was considered adequate for
analysis if >80% of the attempted genotypes resulted in
identiﬁable products.
Statistical Analysis
Statistical signiﬁcance was determined using GraphPad
Prism Software version 5 (La Jolla, CA). Overall survival
was analyzed by Kaplan-Meier curves, and the log-rank
(Mantel-Cox) test was used to determine differences in
survival. Statistical signiﬁcance was deﬁned as P < 0.05.
Two-tailed Student’s t-tests were used to compare time
points.
Results
PTEN and TP53 Loci Are Concurrently Deleted in Many
Human LMS and HGUPS Tumors
We performed mutational analysis of 40 human LMS
samples and 7 normal myometria using OncoMap3 Core and
Extended panels,15 assessing 1047 mutations from 116 genes
(Supplemental Table S1 and Supplemental Table S2). Inde-
pendent validation of 73 candidate mutations on 44 genes
only conﬁrmed six mutations in two genes, EGFR and TP53,
none of which co-occurred in the same tumor sample
(Supplemental Figure S1A). Speciﬁcally, three (7.5%) of the
LMSs harbored a low-frequency germ-line single-nucleotide
polymorphism in EGFR (S703F), and another three cases
(7.5%) carried mutations in TP53 (one V157F and two
R273C amino acid substitutions). Overall, the incidence of
hotspot mutations in the most commonly altered oncogenes
and tumor suppressors was extremely low in our LMS cohort,
in accordance with a recent analysis covering fewer candidate
mutations.16The American Journal of Pathology - ajp.amjpathol.orgWe then searched for chromosomal aberrations in several
tumor suppressor loci using published single-nucleotide
polymorphism array analysis17 of DNA from 27 LMSs and
three MFHs/HGUPs paired with their corresponding normal
tissue (Supplemental Figure S1B). (HGUPS, alias undiffer-
entiated sarcoma, has, at times, been coextensive with MFH
or malignant ﬁbrous histiocytoma; a history of the changes in
subclassiﬁcation is given by Matushansky et al.18) The most
frequent alteration observed was partial deletion of chro-
mosome 10 at the PTEN locus, in approximately 50% to 70%
of cases. Moreover, 85% of LMSs showed a reduced copy
number of PTEN and/or TP53. Strikingly, although 11% of
LMS tumors displayed only TP53 loss, 67% harbored
concomitant reduction of both PTEN and TP53 copy num-
bers (Supplemental Figure S1B).
In agreement with the genomic ﬁndings, data mining of
several independent expression proﬁles revealed that human
HGUPS (undifferentiated/MFH) and LMS had signiﬁcantly
lower expression of PTEN and TP53 than either lipo-
sarcomas (Supplemental Figure S1C)19e21 or other STSs
(Supplemental Figure S1D),22 and 33% of HGUPS and LMS
had concomitantly reduced mRNA levels of both PTEN and
TP53.19
In summary, concurrent reduction of PTEN and TP53
levels, resulting from genetic deletions or chromosomal
losses, is characteristic of a large subgroup of human HGUPS
and LMS.
Partial Inactivation of Pten and Tp53 in the SM Lineage
Leads to Various Sarcoma Subtypes with Ability to
Metastasize
These ﬁndings encouraged us to investigate the differential
effect of reduced gene dosage of Pten, Tp53, or combinations
of both in early progenitors of the SM lineage. We, therefore,
crossbred PtenL/LTp53L/L (PtenL/L7,8 and Tp53L/L9) and Tagln
(transgelin)-cre23 mice to generate all of the possible genetic
combinations of mice defective in one or both alleles of
these two tumor suppressors. Immunostaining of Tagln-cre/
Rosa26-LSL-LacZ reporter mouse11 tissues revealed diffuse
LacZ signal in the myometrium and in the SM layers of the
bladder (Supplemental Figure S2A), conﬁrming cre-mediated
recombination in the SM of Tagln-cre mice. The progeny of
the Tagln-cre x PtenL/LTp53L/L crosses followed an almost
mendelian distribution, except for Tagln-creþ/PtenD/D
Tp53D/D and Tagln-creþ/PtenD/DTp53D/þ mice, which were
deemed less viable. Tagln-creþ/PtenD/DTp53þ/þ mice were
smaller at birth and presented complex pathological charac-
teristics, which resulted in a dramatically reduced lifespan
(average, 68.2  9.5 days). This is consistent with our
previous report24 showing that these mice develop SM
hyperplasia and incipient abdominal leiomyosarcomas.
Only 4 (10%) of 40 Tagln-creþ/PtenD/þTp53þ/þ (here-
after, PtenD/þTp53þ/þ) mice developed sarcomas (Table 2),
suggesting that heterozygous Pten works as a strong tumor
suppressor in this context. Sarcoma penetrance in Tagln-2019
Table 2 Incidence of HGUPS, LMS, and CS per Genotype
Genotype
Incidence*
Tumor distribution*
Tagln-cre Pten Tp53 HGUPS LMS CS
þ þ/þ þ/þ 0/28 0/0 0/0 0/0
þ D/þ D/þ 14/37 (38) 9/14 (64.3) 3/14 (21.4) 2/14 (14.3)
þ D/þ þ/þ 4/40 (10) 2/4 (50) 1/4 (25) 1/4 (25)
þ þ/þ D/þ 6/27 (22.2) 2/6 (33.3) 3/6 (50) 1/6 (22.2)
*Data are given as number/total (percentage).
þ, wild-type allele; D, ﬂoxed allele; CS, carcinosarcomas; HGUPS, high-grade undifferentiated pleomorphic sarcomas; LMS, leiomyosarcomas.
Guijarro et alcreþ/Ptenþ/þTp53D/þ (hereafter, Ptenþ/þTp53D/þ) mice was
higher, affecting 6 (22%) of 27 mice. Concomitant inacti-
vation of a Tp53 and a Pten allele led to the highest sarcoma
incidence, affecting 14 (38%) of 37 Tagln-creþ/PtenD/þ
Tp53D/þ mice (hereafter, PtenD/þTp53D/þ), and the shortest
overall survival (244.1  29 days) compared with Pten
heterozygous mice (376.9  33 days; P Z 0.0024) and
Tp53 heterozygous mice (546.4  36 days; P < 0.0001)
(Figure 1A). Partial loss of Pten, thus, synergizes with Tp53
heterozygosity in sarcomagenesis by accelerating tumori-
genesis, progression, or both.
Histopathological evaluationofPtenD/þTp53D/þ andPtenþ/þ
Tp53D/þ tumors led to the diagnosis of a variety of lesions
(Table 2), including HGUPS, LMS, and CS, predominantlyFigure 1 Conditional Pten and Tp53 heterozygous deletion in the SM lineage
genotypes as a function of days. A statistically signiﬁcant decrease in lifespan
(**PZ 0.0024) and Ptenþ/þTp53D/þmice (***P< 0.0001 ). B: Macroscopic image
HGUPS in a PtenD/þTp53D/þ mouse (bottom panel). C: H&E and IHC stainings of
antibodies against desmin and PCNA. The percentage of PCNA-positive cells is indic
desmin in metastases found in the indicated organs. The top two rows correspond to
E: Top panel, scheme of primers used for Pten and Tp53 PCR-based assays to geno
Bottom panel, electrophoresis of PCR products from genomic DNA isolated from tu
allele after cre-mediated recombination. F: Gel electrophoresis of PCR ampliﬁcation
short-term cultures of the corresponding murine tumors. In parenthesis, primer pa
2020affecting the genitourinary tract and the retroperitoneum
(Figure 1B).HGUPSdisplayed cellular atypia, hypercromatic
nuclei, numerous aberrant mitosis, and local areas of necrosis
(Figure 1C). LMSs were characterized by spindle cells with
cigar-shaped nuclei, arranged in intersecting bundles and
positive for SM markers, such as desmin (Figure 1C) or
smooth muscle actin (data not shown). CSs were composed
of their characteristic mixed areas of mesenchymal and
epithelial origin, as shown by positivity for desmin
(Figure 1C) and cytokeratins (data not shown), respectively.
The proliferative index as per PCNA immunostaining was
similar in HGUPS, LMS, and CS (approximately 60%).
Ptenþ/þTp53D/þ sarcomas included 50% LMS and 33.3%
HGUPS, whereas PtenD/þTp53D/þ mice had a higherleads to HGUPS, LMS, and CS. A: Survival plot for mice with the indicated
was found for PtenD/þTp53D/þ mice compared with PtenD/þTp53þ/þ mice
s of a uterine LMS in a Ptenþ/þTp53D/þmouse (top panel) and an abdominal
sections of the three sarcoma subtypes found on PtenD/þTp53D/þ mice with
ated. Scale bars,20 (250 mm);40 (125 mm). D: H&E and IHC staining for
a Ptenþ/þTp53D/þ LMS, and the bottom panel depicts a PtenD/þTp53D/þ CS.
type or sequence for mutations and/or deletions. ORF, open reading frame.
mor tissue using the indicated primer pairs. Floxed denotes the recombined
products for Tp53 (top two lanes) and Pten (bottom ﬁve lanes) in DNA from
irs used for detection. GAPDH is used as a loading control.
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Notch in Pten/Tp53-Inactivated Sarcomasincidence of undifferentiated sarcomas (64% HGUPS and
21% LMS). CS incidence was 22% and 14%, respectively
(Table 2). Both mouse lines also developed nonmesenchymal
tumors, as summarized in Supplemental Table S3.
Some PtenD/þTp53þ/þ, Ptenþ/þTp53D/þ, and PtenD/þ
Tp53D/þ tumors (particularly the CSs) were able to colonize
distant organs, including liver, pancreas, or lungs (Figure 1D),
but metastases were detected much earlier in the life of
PtenD/þTp53D/þmice. This observation underlines the ability
of the PtenD/þTp53D/þ model to recapitulate the highly
aggressive behavior of human sarcomas, which normally
display hematogeneous spread through the portal system to
reach distal organs.
Pten But Not Tp53 Is Haploinsufﬁcient for Sarcoma
Tumor Suppression in PtenD/þ Tp53D/þ Mice
We asked whether sarcoma formation associates with loss of
heterozygosity of the remaining Pten and/or Tp53 wild-type
alleles in PtenD/þTp53D/þ and Ptenþ/þTp53D/þ mice. The
wild-type allele of Pten was occasionally found partially
deleted (3 of 10 PtenD/þTp53D/þand 0 of 4 Ptenþ/þTp53D/þ),
and sequencing did not reveal point mutations (Figure 1, E
and F, and Supplemental Table S4). The remaining Tp53
allele, however, was invariably found mutated in short-term
cultures derived from resected murine tumors (six of six
cases), recurrently in the DNA-binding domain (Sup-
plemental Table S4). This suggests that Tp53 must be fully
inactivated to allow sarcomagenesis initiated by Pten het-
erozygosity to proceed. We conclude that Pten is generally
haploinsufﬁcient for sarcoma tumor suppression, whereas
there is strong selective pressure to completely abrogate Tp53
function to allow sarcoma development.
Interestingly, tumor cells fromPtenD/þTp53D/þ andPtenþ/þ
Tp53D/þ mice showed numerous structural and numerical
changes (Supplemental Figure S3). These tumors, thus, re-
capitulate the chromosomal instability characteristic of the
corresponding human lesions.
Pten Down-Regulation in Ptenþ/þTp53D/þ Bone
MarroweDerived Mesenchymal Stem Cells and in Tumor
Cells Increases Their Clonogenic and Invasive Capacity
PtenD/þTp53D/þ tumors progress much more rapidly than
Ptenþ/þTp53D/þ lesions. To determine which advantage Pten
suppression confers on Tp53-deﬁcient murine tumors, we
compared the growth properties of BM-derived mesenchymal
stem cells (MSCs) from these mice, as a surrogate of the plau-
sible cell of origin of HGUPS and LMS.17,25,26 We ﬁrst
conﬁrmed that a fraction of BM-MSC and their progeny are
targeted in our mouse model on Cre recombination using
ﬂuorescence-activated cell sorter analysis ofTagln-cre/Rosa26-
LSL-EGFP mice BM. This analysis showed 6.46%  0.52%
(nZ 4) of LinScaIþc-kit cells, which encompass the MSC
pool, as positive for GFP (Supplemental Figure S2B). Then,
BM-MSCs were isolated from PtenL/þTp53L/þ and Ptenþ/þThe American Journal of Pathology - ajp.amjpathol.orgTp53L/þ Cre mice, and recombination was acutely triggered
by Ad5-CMV-Cre-GFP infection in vitro. We observed that
after infection, PtenD/þTp53D/þ MSCs displayed signiﬁcantly
higher clonogenic potential (Figure 2A) and proliferative
capacity (Figure 2B) than Ptenþ/þTp53D/þ or wild-typeMSCs.
These results were conﬁrmed in MSCs isolated from the cor-
responding PtenD/þTp53D/þ and Ptenþ/þTp53D/þ mice, in
which recombination had occurred genetically, in vivo (data not
shown).
To determine whether the enhanced oncogenic properties
of PtenD/þTp53D/þ tumor cells were caused by Pten down-
regulation, we stably infected two cell lines derived from
Ptenþ/þTp53D/þ HGUPS with a lentivirus carrying a short-
hairpin RNA for Pten (shPten). In both cell lines, reduced
Pten expression (Figure 2C) was accompanied by a signiﬁ-
cant increase in colony formation (Figure 2D) and cell
invasion (Figure 2F), without major effects in proliferation
(Figure 2E). These in vitro properties are consistent with the
more aggressive tumor behavior and reduced overall
survival observed in PtenD/þTp53D/þmice; they further
indicate that the differences between PtenD/þTp53D/þand
Ptenþ/þTp53D/þ tumor behavior can be directly attributed
to lower Pten levels.
Notch Signaling Is Increased in PtenD/þTp53D/þ
Murine HGUPS Compared with Ptenþ/þTp53D/þ Tumors
Wecompared the gene expression proﬁles ofPtenD/þTp53D/þ
(n Z 4) and Ptenþ/þTp53D/þ (n Z 5) murine HGUPS tis-
sues to identify transcriptional changes that could account for
their distinct phenotypic behavior. Functional annotation
(DAVID)27,28 and GSEA12,13 revealed that the most signiﬁ-
cantly up-regulated pathways in PtenD/þTp53D/þ tumors
were Notch (PZ 0.012), Akt (PZ 0.011), mitogen-activated
protein kinase (MAPK; P < 0.0001), and NF-kB (P <
0.0001) (Figure 3, A and B). Further analyses of individual
genes within those pathways showed Notch1, Pdk1, Jak1,
Tradd, Map3k9, Pak2, and Ripk1 as signiﬁcantly up-
regulated (Figure 3C). Array data were validated by quanti-
tative real-time PCR for Notch1, Jak1, and Ripk1 in PtenD/þ
Tp53D/þ and Ptenþ/þTp53D/þ tumor-derived cell lines
(Figure 3D). These data demonstrate that partial loss of Pten
in a Tp53 heterozygous context results in a distinct molecular
proﬁle, which includes up-regulation of Notch signaling.
Increased Notch Signaling Partially Accounts for the
Greater Invasive and Clonogenic Potential of PtenD/þ
Tp53D/þ Murine HGUPS
Because the Notch pathway exerts key roles in tumorigen-
esis,29 maintains MSCs in an undifferentiated state,30 and can
be targeted pharmacologically,31 we selected it for further
analyses.We sought to determinewhetherNotch signalingwas
responsible for the increased invasive and clonogenic potential
of PtenD/þTp53D/þ tumor cells compared with Ptenþ/þ
Tp53D/þ cells. Indeed, treatment with the g-secretase2021
Figure 2 Pten silencing in Tp53 heterozygous
mesenchymal stem cells and tumor cells exacer-
bates their oncogenic behavior. Murine BM-MSCs
were infected with Ad5-CMV-Cre-GFP and sub-
jected to colony formation (A) and proliferation
assays (B). Relative proliferation at day 6 after
infection is shown. C: Western blot analysis of two
murine Ptenþ/þTp53D/þ HGUPS cell lines infected
with shPten (sh) or nonsilencing control (V) and
parental (C) cells. Colony formation assay (quan-
titated in the adjacent histogram) (D) and growth
curve (E) of shPten-infected HGPUS cells compared
with nonsilencing control. F: Representative
images of a transwell invasion assay on two HGUPS
cell lines transduced with nonsilencing control or
shPten lentivirus. Graphs indicate relative number
of cells per ﬁeld. B and DeF: Representative of
three independent experiments  SD. *P < 0.05,
**P < 0.01, and ***P < 0.001.
Guijarro et alinhibitor (GSI) Compound E, which suppressed Hes1 levels
(Figure 4A), reduced the invasive capacity of PtenD/þTp53D/þ
cells (Figure 4B), suggesting that these tumors particularly
rely on Notch signaling for their aggressive behavior.
Surprisingly, treatment of Ptenþ/þTp53D/þ cells had the
opposite effect (Figure 4B). Furthermore, treatment with
this GSI counteracted the ability of shPten, which
induced Hes-1 levels (Figure 4C), to enhance the clono-
genic and invasive potential of Ptenþ/þTp53D/þ sarcoma
cells (Figure 4, D and E). These results demonstrate that
Notch activation subsequent to Pten silencing in a Tp53-
deﬁcient background contributes to the increased ag-
gressiveness of double-heterozygous tumors. In sum,
higher Notch signaling is characteristic of HGUPS that
have dual Pten/Tp53 suppression, and it may contribute
to a faster disease course in patients with this genetic
makeup.
Discussion
The extremely low frequency of point mutations in
conventional oncogenes, highlighted by our extensive
analysis of tumor samples, has typically limited our ability
to model LMS and HGUPS in mice. Herein, we demonstrate
that concurrent chromosomal deletions encompassing the
Pten and Tp53 loci, which are common hallmarks of human
HGUPS and LMS,16 act synergistically to initiate these
tumors in our genetically engineered mice.2022Similar genomic alterations in some LMS and HGUPS32
suggest that they may share common pathways of trans-
formation. Our large-scale mutation proﬁling of human
LMS using the Oncomap platform found nucleotide changes
in TP53 and EGFR in 6 of 40 patients; other rare mutations
previously reported for HGUPS and LMS were not found in
our cohort, including those in PTEN and HRAS.33e36 These
ﬁndings underline the low incidence of recurrent point
mutations in classic oncogenes and tumor suppressors
characteristic of these tumors. In contrast, published single-
nucleotide polymorphism and gene expression arrays reveal
frequent concurrent 10q22-23 genomic losses and down-
regulation of PTEN37 and TP53,38e42 providing a ratio-
nale for genetically engineering these lesions in mice to
model HGUPS and LMS.
Genetic alterations of TP53 and PTEN are among the most
frequent causal events in many cancers, and their combined
inactivation has shown strong oncogenic potential in other
mouse models. Loss of Tp53 alone was sufﬁcient to initiate
sarcomas in our model, although tumor progression was
dramatically accelerated in conjunction with Pten inactiva-
tion. Conditional inactivation of both Pten and Tp53 in other
mouse models has been shown to cause metastatic bladder
cancer,43 glioblastoma,44 and invasive, but not metastatic,
prostate cancer.7 In contrast to our ﬁndings, those studies
showed Tp53 depletion to be generally insufﬁcient for
transformation: both alleles of Tp53 and Pten needed to be
inactivated to generate tumors that recapitulate the biologicalajp.amjpathol.org - The American Journal of Pathology
Figure 3 The Notch signaling pathway is up-regulated in PtenD/þTp53D/þ murine HGUPS. A: Histogram of pathways up-regulated in PtenD/þTp53D/þ
tumors according to DAVID.27,28 B: GSEA performed on genes differentially expressed (fold change of >1.25 and P < 0.05) in PtenD/þTp53D/þ compared with
Ptenþ/þTp53D/þ. C: Selected differentially expressed genes found in relevant pathways. D: Validation of the RNA array data by quantitative real-time RT-PCR
comparing PtenD/þTp53D/þ and Ptenþ/þTp53D/þ murine HGUPS cell lines. The fold change (FC) is shown for different genes. GAPDH was used for normali-
zation. Error bars represent SD between two experimental replicates. *P < 0.05, **P < 0.01.
Notch in Pten/Tp53-Inactivated Sarcomasbehavior of the corresponding human lesions. These differ-
ences in results suggest that there are context-dependent
tumor suppressor roles for Tp53 and Pten in epithelial and
mesenchymal transformation and tumorigenesis.
Complete Pten inactivation has been shown to trigger
a prosenescence response (Pten-initiated cellular senes-
cence), which acts as a potent antitumoral barrier in vivo7 that
can be bypassed by Tp53 genetic silencing.7,45 In our model,
partial Pten inactivation was accompanied by Tp53 point
mutations in both PtenD/þTp53þ/þ (data not shown) and
PtenD/þTp53D/þ murine tumors. This could explain why
human sarcomas with complex genetics do not select for
complete loss of PTENdpartial loss has been reported to
occur in 39% of 111 LMS and HGUPS33dand emphasize
the signiﬁcance of PTEN haploinsufﬁciency for sarcoma
initiation and progression.
Partial Pten/Tp53 inactivation in our mice led to multiple
histological phenotypes (HGUPS, LMS, and CS), suggesting
a commonmolecular32 and a common cellular origin for these
tumors. The appearance of multiple histological phenotypes
characterized by various degrees of differentiation might be
explained by targeting of different cells of origin that repre-
sent various stages of differentiation along the SM lineage,
each producing a speciﬁc histological phenotype. Alterna-
tively, it could be that a speciﬁc cell of origin, perhaps
a progenitor, subsequently differentiates into multiple tumor
phenotypes through the accumulation of stochastic secondary
events. In fact, the variety of tumors observed, ranging fromThe American Journal of Pathology - ajp.amjpathol.orgHGUPS to well-differentiated LMS, may also reﬂect how
transforming events affect the ability of a single precursor cell
to differentiate.
In recent years, there has been much debate over the cell
of origin for various sarcoma subtypes, including synovial,
Ewing, and HGUPS. Xenografted and genetically engi-
neered mouse models25,46,47 have revealed some of these
tumors to be derived from mesenchymal stem cells or
progenitors, rather than somatic, differentiated cell types.
We propose that cre-mediated inactivation of Pten or Tp53
target MSC-like cells committed toward the SM lineage.
The fact that there were no other tumors of mesenchymal
origin (ie, liposarcomas, osteosarcomas, or chondrosarcomas)
supports this hypothesis. It is also possible, however, that
other mesenchymal lineages, such as the adipocytic or
chondrocytic, are not as susceptible to transformation trig-
gered by Tp53 and/or Pten defects. The appearance of
carcinosarcomas is particularly puzzling: they might origi-
nate from a common epithelial/mesenchymal precursor
within the uterus,48 or the carcinomatous component might
result from transgene expression in some epithelial cells of
the uterus, supporting a combined tumor model.49 A third
possibility is that transformation of the epithelium could be
nonecell autonomous, resulting from aberrant signaling
from the surrounding sarcoma cells.
One of the salient characteristics of our genetically engi-
neered mouse model is its spontaneous development of
metastases. We found metastases in both Ptenþ/þTp53D/þ2023
Figure 4 Increased Notch signaling partially accounts for the higher invasive and clonogenic potential of PtenD/þTp53D/þ sarcoma. A: Relative expression
of Hes1 by quantitative real-time RT-PCR of PtenD/þTp53D/þ and Ptenþ/þTp53D/þ HGUPS murine sarcoma cell lines, with (þ) or without () 500 nmol/L
Compound E. Relative values referred to R18S1, used as a housekeeping gene. B, Left panel: Transwell invasion assay for PtenD/þTp53D/þ and Ptenþ/þTp53D/þ
HGUPS sarcoma cell lines, with (þ) or without () 500 nmol/L Compound E. Data are given as means  SD. Right panel: Representative images of
the invasion assay. C: Relative expression of Hes1 in Ptenþ/þTp53D/þ HGUPS transduced with shPten or vector (v), in the presence (þ) or absence () of
500 nmol/L Compound E. Clonability (D) and transwell invasion assay (E) in Ptenþ/þTp53D/þ HGUPS transduced with shPten or vector (v), with (þ) or without
() 500 nmol/L Compound E. Data are given as means  SD. *P < 0.05, **P < 0.01, and ***P < 0.001.
Guijarro et aland PtenD/þTp53D/þ mice, although the combined inactiva-
tion of Tp53 and Pten deﬁnes a subgroup of tumors with
much faster dissemination. This suggests a particularly
aggressive course of Pten/Tp53-inactivated tumors, as sup-
ported by our in vitro data.
Pten suppression in a Tp53 heterozygous background
strongly promoted the clonogenic capacity of MSCs and the
invasive potential of established murine tumor cell lines.
Faster proliferation was also apparent in MSCs in response
to partial Pten/Tp53 conditional inactivation, but not in
already established Ptenþ/þTp53D/þ tumors, perhaps
because of additional hits acquired during tumor progres-
sion, which are partly redundant with the proproliferative
effects of Pten suppression. Nonetheless, the suppression of
Pten in a Tp53-inactivated background induced more
malignant behavior and more rapid disease course.
Expression proﬁling of PtenD/þTp53D/þ and Ptenþ/þ
Tp53D/þ tumors revealed an up-regulation of the MAPK
pathway on Pten inactivation. Aberrant MAPK signaling
occurs inmany humanmalignancies,where it promotes tumor
proliferation andmetastasis. In particular, Ras, a central signal
transduction mediator, has been previously involved in sar-
comagenesis.5 Therefore, selective inhibition of the MAPK
pathway, currently possible through highly speciﬁc com-
pounds being tested in the clinic (ie, BRAF and MEK inhi-
bitors), may serve as a viable therapeutic approach against
double Pten/Tp53-defective HGUPS.2024In addition, the microarray proﬁle showed a signiﬁcant
up-regulation of the Notch signaling pathway in Pten/Tp53
heterozygous tumors compared with Pten wt/Tp53 hetero-
zygous tumors. Furthermore, the increased invasive and
clonogenic potentials conferred by Pten suppression (or
shPten) were largely dependent on Notch signaling. The
highly conserved Notch pathway plays critical roles in
development and cancer in a cell-speciﬁc manner, leading to
oncogenic or tumor-suppressive effects in different
contexts.29 Tumor-promoting effects of Notch signaling have
been described in human osteosarcoma,50 Ewing sarcoma,51
and rhabdomyosarcoma,52 and they have recently been
implicated in the regulation of self-renewal in HGUPS.53 A
link between NOTCH and PTEN deregulation has been re-
ported in human melanoma, in which tumors lacking PTEN
show hyperactivated phosphatidylinositol 3-kinase/AKT
signaling and NOTCH1 up-regulation via NF-kB.54 Inter-
estingly, the NF-kB pathway was found signiﬁcantly up-
regulated in PtenD/þTp53D/þ mice compared with Ptenþ/þ
Tp53D/þ mice, according to our array data (Figure 3).
Conversely, in other tumor models, such as T-ALL, phos-
phatidylinositol 3-kinaseeAKT has been shown to
contribute to NOTCH1-induced transformation, with the
PTEN status determining the cellular response to GSI.55 In
our system, treatment of Pten/Tp53 heterozygous HGUPSs
with a GSI strongly inhibited their in vitro oncogenic prop-
erties, in contrast to Tp53 heterozygous HGUPSs thatajp.amjpathol.org - The American Journal of Pathology
Notch in Pten/Tp53-Inactivated Sarcomasparadoxically showed opposite effects. These data lend
support to the notion that context is important for determining
the effects of Notch signaling and inhibition.
At present, most HGUPSs and LMSs are treated with
similar chemotherapy regimens, despite their histological
and molecular heterogeneity.18,56 Previous observations in
a Pten-null murine LMS model24 and data not shown
revealed antiproliferative effects of mTor inhibition in both
Pten-wt and Pten-het murine HGUPS. However, inhibition
of mTOR has been deemed incapable of achieving durable
therapeutic responses in patients with sarcoma,57 suggesting
the possibility of feedback and compensatory effects, such
as those shown in other tumor types.58 Our observation that
Pten het/Tp53 het murine tumors are particularly sensitive to
Notch inhibition raises the possibility that HGUPS or LMS
patients bearing this genetic makeup might be successfully
treated with NOTCH inhibitors either alone or in combi-
nation with mTOR inhibitors. In contrast, this treatment
might be harmful for PTEN wt/TP53 het cases, according to
our preclinical studies.
These observations suggest that classifying HGUPS and
LMS patients based on tumor genetic and expression cri-
teria could improve patient outcomes by predicting dis-
ease progression and providing a decision-making tool for
designing individualized treatments (as proposed in
Supplemental Figure S4).Acknowledgments
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